Results BASE-CASE RESULTS In the base-case analysis, subcutaneous tirzepatide and oral semaglutide emerged as cost-effective vs subcutaneous liraglutide and subcutaneous semaglutide
Since tirzepatide typically produces greater weight loss (20-25% body weight versus 15-17% with semaglutide at weight loss doses), more tirzepatide users may experience telogen effluvium simply because they lost more weight faster
Patients are encouraged to report suspected adverse reactions to tirzepatide via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
However, your food choices directly impact how well you tolerate the medication and how quickly you see resultsmaking dietary awareness a critical part of your treatment strategy
This perspective is consistent with a recent joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, which identified nutritional and lifestyle priorities as essential components of effective and durable GLP-1based obesity care [146]
17How should Semaglutide tablets be taken
.png)
